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Introduction
Cytokines comprise a heterogeneous group of proteins
of high biological activity. These pleiotropic molecules
are intercellular mediators that, via autocrine and
paracrine way, control fundamental cell functions -
proliferation, differentiation and migration, above all -
and regulate immune reactions, inflammatory processes
and physiological regeneration of tissues.
Excessive and uncontrolled expression of cytokine
genes and their receptors in cancer cells as well as their
increased synthesis in the stromal cells of the cancer site
very often accompany neoplastic processes. Cytokines
and their soluble receptors released to body fluids at
sufficiently high concentrations may be useful markers
for cancer diagnosis, prognosis, and monitoring of
treatment response.
So far, most studies have focused on correlations
between the levels of cytokines and their soluble receptors
in blood serum and clinical and pathological cha-
racteristics of the disease as well as on the significance of
serum cytokine concentrations as independent prognostic
factors [1-5]. In our earlier studies, we have analysed the
concentrations of an array of cytokines of various
activities and their soluble receptors, to select those,
which can prove to be most useful in oncological practice.
Furthermore, for several cancer sites, analyses of cytokine
and soluble cytokine receptor levels related to patient
survival along with multivariate analyses revealed that
some of these mediators might have a value of inde-
pendent prognostic factors [1, 2, 6].
In only a few of the available papers the relationships
between serum cytokine concentrations and the response
to treatment was analysed [7-11]. 
In the study presented here, the potential use of
selected serum cytokine measurements in the monitoring
of treatment of patients with soft tissue sarcomas was
assessed.
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I n t r o d u c t i o n.  The aim of this study was to evaluate the potential clinical use of circulating cytokine measurements in
patients with soft tissue sarcomas during follow-up. 
Pa t i e n t s  a n d  m e t h o d s.  The study comprised 69 patients with pathologically confirmed soft tissue sarcomas. All
patients were treated according to institutional therapeutic protocols. In patients treated by surgery followed by adjuvant radio-
or chemotherapy, cytokine levels were measured before treatment and 7-9 weeks after the treatment was completed. Out of all
cytokines tested, IL-6, IL-8, sTNF RI and VEGF were chosen for monitoring of patients. Commercially available ELISA kits
of R&D, Minneapolis, were used for serum cytokine assessment. Normal cytokine levels were assessed in 50 healthy blood
donors. The Mann-Whitney and Wilcoxon tests were applied for statistical analyses.
R e s u l t s.  Serum IL-6 and IL-8 levels were significantly diminished after treatment in patients with disease remission,
while in those with recurrent disease (local recurrences and/or metastases) no significant changes in serum cytokine
concentrations was observed. Elevated pre-treatment serum IL-6 and sTNF RI concentrations were found more often in
patients with soft tissue sarcomas with recurrent disease after treatment than in those who responded to treatment, but this
difference has not reached statistical significance. Patients with recurrent disease presented significantly higher concentrations
of serum IL-6, IL-8 and sTNF RI, as compared with patients with remissions. 
C o n c l u s i o n.  In summary, out data suggest that changes in serum levels of the assessed cytokines may have a value of
a follow-up marker, especially in patients with soft tissue sarcomas, where no standard tumour marker is known.
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The study was approved by CCIO Bio-Ethics Committee
according to Good Clinical Practice guidelines and all patients
gave their informed consent.
Patients and methods
The study comprised 69 patients with soft tissue sarcomas. The
characteristics of the patients is presented in Table I. All
diagnoses were histologically confirmed. Patients with multiple
cancers or with existing systemic inflammatory conditions were
excluded from the study.
In all patients, serum cytokine levels were measured before
and after treatment. Only patients treated with curative intent
(surgical treatment with adjuvant radio or chemotherapy), with
no signs of distant metastases at baseline, were included.
Patients were followed-up for the median time of over
3 years for the survivors.
Blood samples of 10 ml of were drawn before and after
treatment. After clotting, the sera were collected by centrifuga-
tion, and stored at –70°C until assayed. The normal serum
concentration ranges of cytokines and their soluble receptors
were determined in 50 healthy volunteers [2].
Concentrations of cytokines and cytokine receptors were
measured by enzyme-linked immunosorbent assay (ELISA) with
the use of commercially available kits of R&D Systems,
Minneapolis, USA. The tests were performed according to the
manufacturer’s instructions.
S t a t i s t i c a l  a n a l y s e s
The Mann-Whitney test was used to compare independent
samples, for dependent samples the Wilcoxon test was employed.
Results
Of the previously examined serum cytokines and soluble
cytokine receptors (2), those that had been found to relate
to various clinical and pathological features of soft tissue
sarcoma or to have a prognostic value were selected to
assess their use in monitoring the response to treatment.
The following cytokines were studied: IL-6 and IL-8
possessing a prognostic value, and the pro-angiogenic
VEGF as well as the soluble TNF receptor I (sTNF RI),
found to correlate with the tumour size. These cytokines
were also characterised by high diagnostic sensitivity.
Tables IIa and IIb present medians and ranges of
serum cytokine concentrations and the percentages of
patients with increased pre- and post-treatment cytokine
levels, in patients with no recurrent disease in long-term
follow-up (33 patients) and in patients with recurrent
disease (36 patients). A statistically significant decrease in
IL-6 (p<0.003) and IL-8 (p<0.001) concentrations was
observed in patients with disease remission after
treatment (Table IIa, Figure 1), but not in patients with
recurrent disease (relapse/metastases, Table IIb).
Furthermore, the pattern of changes of the con-
centrations of cytokines in patients depending on their
clinical course was analysed. Higher proportion patients
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Table II.  Serum cytokine levels in patients with soft tissue sarcomas and the results of treatment
a/  disease remission
Cytokines Before treatment Patients with elevated After treatment p value Patients with elevated 
median range pg/ml serum levels, % median range pg/ml serum levels, %
IL-6 2.1 (0.7-135) 16/33 (48%) 1.1 (0.7-7.1) 0.003 6/32 (19%)
IL-8 14.2 (7.6-100.5) 19/33 (57%) 10.1 (10-28.7) 0.001 10/32 (31%)
VEGF 368 (50-1527) 19/32 (59%) 312 (61-1387) NS 15/33 (45%)
sTNF RI 1359 (743-3633) 15/26 (58%) 1367 (600-3120) NS 21/31 (68%)
NS = Not significant
b/ recurrent disease
Cytokines Before treatment Patients with elevated After treatment p value Patients with elevated 
median range pg/ml serum levels, % median range pg/ml serum levels, %
IL-6 4.0 (0.7-129) 23/36 (64%) 3.2 (0.7-86.5) NS 20/36 (55%)
IL-8 13.8 (10-149) 21/36 (58%) 13.3 (10-220) NS 20/36 (55%)
VEGF 286 (30-2000) 17/34 (50%) 430 (29-2000) NS 20/35 (57%)
sTNF RI 1288 (898-4186) 22/31 (71%) 1733 (744-5000) NS 29/36 (80%)
NS = Not significant
Table I.  Patient characteristics
Number of  patients (%)
n=69
Gender
male 33 (48)
female 36 (52)
Age 18-84 (median 52  years)
Tumour pathology
liposarcomas 20 (29.1)
malignant schwannomas 7 (10.1)
synovial sarcomas 8 (11.6)
MFH 11 (15.9)
leiomyosarcomas 7 (10.1)
others 16 (23.2)
Tumour size
<10 cm 30 (43.5)
≥10 cm 39 (56.5)
Tumour grade
G1 11 (15.9)
G2 24 (34.8)
G3 34 (49.3)
with recurrent disease than patients with disease
remission presented elevated pre-treatment IL-6 and
sTNF RI levels. However, these differences proved not
statistically significant. On the other hand, significantly
higher post-treatment concentrations of IL-6 (p<0.001),
IL-8 (p<0.05) and sTNF RI (p<0.02) were observed in
patients with recurrent disease than in those with
remission (Figure 2).
Discussion
Determination of pre-treatment cytokine/soluble cytokine
receptor levels in the blood serum may provide a useful
prognostic tool and may enable a better stratification of
patients for treatment. This applies especially to the
cancers with no “classical” cancer markers known, such as
soft tissue sarcomas. Therefore, it is necessary to search
for the suitable markers which might be applied in widely
understood diagnostics. Cytokines and their soluble
receptors could serve this purpose. However, only few
papers have dealt with this issue, in soft tissue sarcomas
in particular [2, 11]. Much more frequently, cytokine
levels have been related to specific clinicopathological
features and prognosis than to treatment response [1, 3, 8,
9, 12-14]. To date, in patients with soft tissue sarcomas,
the analysis of serum cytokine concentrations during
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Figure 1. Serum IL-6 and IL-8 concentrations (ranges and medians) in patients before treatment 
and in patients after treatment with no recurrent disease
Figure 2. Serum IL-6 and IL-8 and sTNF RI concentrations (ranges and medians) in patients after treatment
depending on clinical status
follow-up were the subject of only a limited number of
studies, and the results obtained were inconsistent [2, 8, 9,
11].
Based on our previous data, the cytokines that play a
role of important prognostic factors as well as those that
correlate with various clinical and pathological features in
patients with soft tissue sarcomas were selected for the
current study, i.e. serum IL-6 and IL-8 shown to be
independent prognostic factors, and VEGF and sTNF
RI found to correlate with tumour size [2]. In this study,
we have examined the potential use of the measurements
of these cytokines in monitoring response to treatment.
The subject of our analysis was not only the impact of
treatment on cytokine concentrations. We have also
studied the changes of serum cytokine levels depending
on the response to treatment.
In patients with post-treatment disease remission,
a statistically significant reduction in IL-6 and IL-8
concentrations was found. In contrast, in patients with
recurrent disease (relapse/metastases), no statistically
significant changes of serum IL-6 and IL-8 levels were
observed. This may result from the fact that high
percentage of patients with recurrent disease presented
increased IL-6 levels already before treatment. On the
other hand, when changes in cytokine concentrations
were analysed as a function of the clinical status of
patients, the proportion of patients with increased pre-
treatment IL-6 and sTNF levels was higher among those
with recurrent disease than in those with disease
remission, but no statistical significance was reached.
However, statistically significantly higher concentrations
of prognostic cytokines, IL-6 and IL-8, and of sTNF RI
were shown after treatment in patients with recurrent
disease as compared with those with disease remission.
In the previously investigated cancer sites, we have
shown markedly higher concentrations of sTNF RI, but
not of TNFα [1, 2, 6]. The TNF RI (55 kD) is a surface
receptor, expressed by basically all cells, but first of all by
epithelial cells. Both TNF RI and RII, but TNF RI in
particular, contains the so-called death domains that
trigger the apoptotic process following the receptor-ligand
binding. Therefore, the release of TNF receptors by
cancer cells is considered a likely element of cellular
defence against apoptosis, though no strong evidence
confirms this idea [15].
Summary. In patients with soft tissue sarcomas,
a change in the serum cytokine concentrations during
follow-up is related to disease recurrence. In particular,
the measurements of serum IL-6, IL-8 and sTNF RI
levels may be useful in monitoring of treatment response
in patients with soft tissue sarcomas, where no standard
cancer marker is known.
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